Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alimera Sciences (ALIM)
NASDAQ:ALIM
Alimera (ALIM) Stock Price & Analysis
242 Followers
ALIM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.56 - $4.38
Previous Close$3.46
Volume2.60K
Average Volume (3M)71.86K
Market Cap
$183.82M
Enterprise Value$233.84M
Total Cash (Recent Filing)$12.06M
Total Debt (Recent Filing)$64.68M
Price to Earnings (P/E)-1.6
Beta1.52
Next Earnings
May 14, 2024EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding52,354,450
10 Day Avg. Volume26,331
30 Day Avg. Volume71,864
Standard Deviation0.22
R-Squared0.08
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-3.54
Price to Sales (P/S)2.26
Price to Cash Flow (P/CF)12.00
P/FCF Ratio5.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.90
Enterprise Value/Gross Profit3.34
Enterprise Value/Ebitda-2.54K
Forecast
1Y Price Target
$8.00Price Target Upside126.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Alimera News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ALIM FAQ
What was Alimera Sciences’s price range in the past 12 months?
Alimera Sciences lowest stock price was $1.56 and its highest was $4.38 in the past 12 months.
What is Alimera Sciences’s market cap?
Currently, no data Available
When is Alimera Sciences’s upcoming earnings report date?
Alimera Sciences’s upcoming earnings report date is May 14, 2024 which is in 10 days.
How were Alimera Sciences’s earnings last quarter?
Alimera Sciences released its earnings results on Mar 07, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.07.
Is Alimera Sciences overvalued?
According to Wall Street analysts Alimera Sciences’s price is currently Undervalued.
Does Alimera Sciences pay dividends?
Alimera Sciences does not currently pay dividends.
What is Alimera Sciences’s EPS estimate?
Alimera Sciences’s EPS estimate is -$0.06.
How many shares outstanding does Alimera Sciences have?
Alimera Sciences has 52,374,687 shares outstanding.
What happened to Alimera Sciences’s price movement after its last earnings report?
Alimera Sciences reported an EPS of -$0.07 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went up 0.775%.
Which hedge fund is a major shareholder of Alimera Sciences?
Among the largest hedge funds holding Alimera Sciences’s share is Blackstone Inc.. It holds Alimera Sciences’s shares valued at N/A.
---
Alimera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (126.63% Upside)
$8.00 (126.63% Upside)
Hedge Fund Trend
Decreased
By 10.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.85%
12-Months-Change
Fundamentals
Return on Equity
-158.76%
Trailing 12-Months
Asset Growth
260.37%
Trailing 12-Months
Company Description
Alimera Sciences
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
---
ALIM Earnings Call
Q4 2024
0:00 / 0:00
---
ALIM Stock 12 Months Forecast
Average Price Target
$8.00
▲(126.63% Upside)
Technical Analysis
Bausch Health Companies
―
Eagle Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Traws Pharma
―
Best Analysts Covering ALIM
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-0.28%
reiterated a buy rating 2 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -0.28% per trade.
---